Tradestie Institutional Equity Comparison Engine

DSGN vs TBPH โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

TBPH Overall Edge

TBPH Captures Institutional Edge (3โ€“1 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Theravance Biopharma, Inc. (TBPH) driven by superior Valuation, Growth & Margin, Momentum & Technical while DSGN counters with relative strength in Options & Structure. Fundamentally, DSGN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus TBPH at 13.4x Forward P/E and 8.9% operating margin (-20.9% YoY). In options structure, DSGN sits in BREAKDOWN (13th %ile IV; Dealer Gamma Walls on Pro) against TBPH sits in UNCLASSIFIED (16th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner TBPH
DSGN N/M vs TBPH 13.4x Fwd P/E
Growth & Margin Winner TBPH
Op Margin 0.0% vs 8.9% ยท YoY +0.0% vs -20.9%
Momentum & Technical Winner TBPH
1Y +40.8% vs +21.0% ยท 52W Pos 30% vs 50%
Options & Structure Winner DSGN
BREAKDOWN (13th %ile IV) vs UNCLASSIFIED (16th %ile IV)
DSGN NASDAQ
Design Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-5.06% 1D
Market Cap $677.5M
1M Return -3.59%
1Y Return +40.79%
Forward P/E N/M
Unified AI Score
49.9 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 63.0 Mom 54.0
TBPH NASDAQ
Theravance Biopharma, Inc.
Pharmaceutical Preparations
$17.03
+0.0% 1D
Market Cap $884.2M
1M Return +0.12%
1Y Return +21.04%
Forward P/E 13.4x
Unified AI Score
54.9 / 100 HOLD
Tech 65.0 Fund 52.0 Flow 50.0 Mom 35.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DSGN +40.79% TBPH +21.04% Spread: +80.2 pp (DSGN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
DSGN TTM Op. Margin: 0.0% TBPH TTM Op. Margin: 8.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DSGN vs TBPH. Trailing 12-month operating profitability (DSGN 0.0% vs TBPH 8.9%) and valuation multiples (DSGN N/M vs TBPH 13.4x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DSGN (1) vs TBPH (9)
Institutional Metric DSGN TBPH Criterion Row Winner
Market Capitalization Scale $677.5M $884.2M Larger Scale TBPH
Trailing P/E Ratio Valuation N/M 16.4x Lower Multiple TBPH
Forward P/E Ratio Valuation N/M 13.4x Lower Multiple TBPH
Revenue Growth (YoY) Growth +0.0% -20.9% Higher Growth DSGN
Operating Margin (TTM) Profitability 0.0% 8.9% Higher Margin TBPH
Net Profit Margin Profitability 0.0% 51.6% Higher Margin TBPH
Return on Equity (ROE) Capital Efficiency -36.9% 20.9% Higher ROE TBPH
52-Week Range Position Momentum 30% ($7โ€“$17) 50% ($13โ€“$21) Stronger Trend TBPH
Beta / 30D Volatility Risk Regime 1.32ฮฒ ยท 61% Vol 0.48ฮฒ ยท 2% Vol Lower Realized Risk TBPH
Unified Institutional Score Composite Signal 49.9 / 100 (HOLD) 54.9 / 100 (HOLD) Higher Composite TBPH

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DSGN vs TBPH Buy Guide
DSGN BREAKDOWN
139d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live DSGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
TBPH UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live TBPH Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DSGN nor TBPH registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.